BioCentury
ARTICLE | Finance

InDex builds its case

InDex series D investors to get near-term Phase III data in ulcerative colitis

March 3, 2014 8:00 AM UTC

Investors in InDex Pharmaceuticals AB's $20 million series D round won't have to wait long for an inflection point, as the company expects to have Phase III data for Kappaproct in ulcerative colitis next quarter.

The DNA-based immunomodulatory sequence (DIMS) targets toll-like receptor 9 (TLR9). It is in the European Phase III COLLECT trial in patients who have chronic, active treatment-refractory UC. The compound is applied locally to the colon and has Orphan Drug designation in the EU...